HOME >> MEDICINE >> NEWS
Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR

Philadelphia, PA., May 19, 2003 Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that a landmark analysis of studies comparing antidepressant treatments demonstrated that significantly more patients achieved remission (virtual elimination) of their depression symptoms, and resolution of both emotional and physical symptoms, when treated with EFFEXOR/EFFEXOR XR (venlafaxine HCl) than with commonly used selective serotonin reuptake inhibitors (SSRIs) or placebo. The analysis was presented in two poster presentations at the American Psychiatric Association's (APA) annual meeting in San Francisco.

The analysis compared EFFEXOR®/EFFEXOR XR to the SSRIs PAXIL® (paroxetine), PROZAC® (fluoxetine), ZOLOFT® (sertraline), LUVOX® (fluvoxamine), and CELEXA (citalopram) and comprised the entire worldwide dataset of Wyeth-sponsored registration and post-marketing, published and unpublished, SSRI-controlled clinical studies of EFFEXOR/EFFEXOR XR to date.

"Given the urgency to treat a patient to remission, these data reinforce EFFEXOR XR as a first-line therapy for depression," says Dr. Eric Hollander, Professor of Psychiatry and Director of Psychopharmacology at Mount Sinai School of Medicine in New York City. "This is important information for physicians as remission is a critical milestone in preventing symptom recurrence and depression relapse."

In one poster it was determined that EFFEXOR/EFFEXOR XR-treated patients had significantly higher remission rates than those treated with the studied SSRIs using standard evaluations including scoring seven or less on the 17-item Hamilton Rating Scale for Depression (HAM-D17) and less than 10 on the Montgomery-Asberg Depression Rating Scale (MADRS).

Specifically, the HAM-D17 evaluation revealed a 41 percent remission rate for EFFEXOR/EFFEXOR XR patients, significantly greater than that of patients receiving an SSRI (35 percent, p<0.001), or a placebo (25 percent,
'"/>

Contact: Douglas Petkus, Wyeth Pharmaceuticals
484-865-5140
Porter Novelli
19-May-2003


Page: 1 2 3 4

Related medicine news :

1. Landmark survey reveals asthma in children remains significantly out of control in the United States
2. Landmark study shows coenzyme Q10 slows progressive decline in Parkinsons disease
3. Landmark XENDOS study shows Xenical prevents or delays the development of type 2 diabetes
4. Landmark study demonstrates potential for nerve regeneration treatment of stroke
5. Landmark study results published in NEJM highlight breakthrough treatment for heart failure
6. Landmark study uncovers reasons behind recurring back injury
7. Landmark clinical trial at 22 medical centers finds implanted heart pumps lengthen and improve lives of terminally ill heart failure patients
8. Landmark dialysis study findings could greatly simplify treatment of kidney disease with peritoneal dialysis
9. Landmark school-based social influences smoking-prevention program found not to work
10. U.S., British scientific societies honor penicillin as International Chemical Landmark
11. CODE-2*: Landmark study on the costs of type 2 diabetes in Europe

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/14/2019)... ... 2019 , ... Impact Advisors, a leading provider of clinical, ... John Stanley, Vice President, has been named one of the “Top 25 Consultants” ... has been recognized in the Excellence in Healthcare category. He will attend the ...
(Date:5/14/2019)... (PRWEB) , ... May 14, 2019 , ... A high ... one of the top health crises in the Houston area and the southern United ... Hispanic men who have sex with men (MSM) and transgender people ...
(Date:5/14/2019)... NASHVILLE, Tenn. (PRWEB) , ... May 14, 2019 ... ... announced today the availability of the Relatient® eRegistration and Check-In solution , ... prior to an appointment. The solution builds on Relatient’s Patient Engagement ...
(Date:5/14/2019)... ISLIP, N.Y. (PRWEB) , ... May 14, 2019 ... ... That’s the price tag put on anti-aging products and procedures, according to market ... registered Physician Assistant specializing in Dermatology with Advanced Dermatology PC , “but ...
(Date:5/14/2019)... ... ... Dr. Steven Shoshany has been treating patients experiencing both acute and long ... therapy device, becoming the first chiropractor in Manhattan to do so. Since January, Dr. ... for treating pain and injuries, into his downtown practice. He recently finished designing a ...
Breaking Medicine News(10 mins):
(Date:5/16/2019)... , ... May 16, 2019 , ... Join John Cogan, ... David Berglund, Global Head Regulatory Operations at AstraZeneca in a live webinar ... technologies can modernize Regulatory Information Management (RIM) systems. , As Regulatory Operating models ...
(Date:5/15/2019)... ... May 15, 2019 , ... Claudius Moore, a seasoned technology ... of Information Technology. Over the last 15 years, Moore has mastered a method ... also creating a high-quality, efficient experience for patients. , Moore will lead AFC’s ...
(Date:5/15/2019)... , ... May 15, 2019 , ... ... Customer Success Report to give prospects better insight on which Emergency Mass ... , The highest rated vendors according to the 2019 Spring Emergency Mass Notification ...
Breaking Medicine Technology:
Cached News: